Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

NCT00422981 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment, So Stated

Interventions

DRUG: AL-108
DRUG: AL-108
DRUG: Placebo

Sponsor

Allon Therapeutics